Full Description
This two-volume set describes the most recent developments in the use of small molecules for targeted therapy in hematology and oncology. In each book a wide range of small molecules are covered. Those of most relevance in hematology include tyrosine kinase inhibitors, immunomodulatory drugs, the IDH-2 inhibitor enasidenib, the BCL-2 inhibitor venetoclax, and the proteasome inhibitor carfilzomib, while, in addition to tyrosine kinase inhibitors, mTOR, MEK, PARP, and multikinase inhibitors and cell cycle and NTRK interacting agents are of particular interest in oncology. For each molecule, chemical structure, mechanism of action, drug targets, and drug interactions are described. The results of preclinical studies and clinical trials are reviewed, with presentation of the latest information on treatment applications. The extensive research into the molecular mechanisms of cancer has heralded a new age of targeted therapy. In presenting key advances in the field, this impressive set will be of interest and value for both researchers and clinicians.
